Drug holiday or not? sarcoma study tests best strategy

NCT ID NCT01303094

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 53 adults with advanced soft tissue sarcoma who had stable disease or improvement after 6 cycles of trabectedin. Half continued the drug, while the other half took a break (drug holiday). The goal was to see which approach better delays cancer progression and reduces side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma uterine corpus sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA UTERINE SARCOMA

Contacts and locations

Locations

CHU Timone Adultes

Marseille, 13385, France
Centre Antoine Lacassagne

Nice, 06189, France
Centre François Baclesse

Caen, 14076, France
Centre Georges François Leclerc

Dijon, 21079, France
Centre Henri Becquerel

Rouen, 76038, France
Centre Jean Perrin

Clermont-Ferrand, 63011, France
Centre Léon Bérard

Lyon, 69008, France
Centre Oscar Lambret

Lille, 59020, France
Centre René Huguenin

Saint-Cloud, 92210, France
Institut Bergonié

Bordeaux, 33076, France
Institut Claudius Regaud

Toulouse, 31052, France
Institut Curie

Paris, 75005, France
Institut Gustave Roussy

Villejuif, 94805, France
Léon Bérard Center

Lyon, 69 008, France
Paoli Calmette Institute

Marseille, 13 273, France
Saint-Jacques Hospital

Besançon, 25 000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.